US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

38.85

+0.49321.29%

Post-market: 38.81-0.0441-0.11%19:30 EDT

Volume:41.81K

Turnover:1.63M

Market Cap:356.29M

PE:- -

High:38.97

Open:38.51

Low:38.51

Close:38.36

52wk High:39.80

52wk Low:30.66

Shares:9.17M

Float Shares:9.17M

Volume Ratio:1.13

T/O Rate:0.46%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Innovative Drugs Face a Key Data Catalyst Window! Can't Tell OS, PFS, and ORR Apart? Here's a Quick Reference Guide! Save It for Later

Yen Rally at a Crossroads as $103 Billion Short Position Looms Over Key Support Level

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/ORR"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.8541,"timestamp":1789156800000,"preClose":38.3609,"halted":0,"volume":41810,"hourTrading":{"tag":"盘后","latestPrice":38.81,"preClose":38.8541,"latestTime":"19:30 EDT","volume":120,"amount":4657.8846,"timestamp":1789169407285,"change":-0.0441,"changeRate":-0.001135,"amplitude":0},"delay":0,"changeRate":0.012856841210711992,"floatShares":9170000,"shares":9170000,"eps":0,"marketStatus":"Market Closed","change":0.4932,"latestTime":"09-11 16:00:00 EDT","open":38.51,"high":38.97,"low":38.51,"amount":1625557.7484000002,"amplitude":0.011991,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":38.3609,"sharesOutstanding":12900000,"nav":38.64,"aum":354328800,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":38.67,"preClose":38.3609,"latestTime":"09:28 EDT","volume":37,"amount":1427.6000820000002,"timestamp":1789133333850,"change":0.3091,"changeRate":0.008058,"amplitude":0.004171},"postHourTrading":{"tag":"盘后","latestPrice":38.81,"preClose":38.8541,"latestTime":"19:30 EDT","volume":120,"amount":4657.8846,"timestamp":1789169407285,"change":-0.0441,"changeRate":-0.001135,"amplitude":0},"volumeRatio":1.131652,"impliedVol":0.1515,"impliedVolPercentile":0.5029},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9170000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.131652,"shares":9170000,"dividePrice":0,"high":38.97,"amplitude":0.011991,"preClose":38.3609,"low":38.51,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":38.8541,"eps":0,"divideRate":0,"volume":41810,"delay":0,"ttmEps":0,"open":38.51,"prevYearClose":34.16,"prevWeekClose":39.1863,"prevMonthClose":38.77,"prevQuarterClose":36.32,"fiveDayClose":39.1754,"twentyDayClose":38.57,"sixtyDayClose":36.65},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1175331559","title":"Innovative Drugs Face a Key Data Catalyst Window! Can't Tell OS, PFS, and ORR Apart? Here's a Quick Reference Guide! Save It for Later","url":"https://stock-news.laohu8.com/highlight/detail?id=1175331559","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175331559?lang=en_us&edition=fundamental","pubTime":"2026-09-11 19:30","pubTimestamp":1789126250,"startTime":"0","endTime":"0","summary":"For innovative drug investors, a major event is on the horizon. This Saturday, September 12th, the 2026 WCLC (World Conference on Lung Cancer) opens its doors, with several leading innovative drug...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","MEDX","06978","ORR","LNGR","159992","IBBQ","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102380640","title":"Yen Rally at a Crossroads as $103 Billion Short Position Looms Over Key Support Level","url":"https://stock-news.laohu8.com/highlight/detail?id=1102380640","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102380640?lang=en_us&edition=fundamental","pubTime":"2026-09-04 11:42","pubTimestamp":1788493323,"startTime":"0","endTime":"0","summary":"During Friday's Asian trading session, the dollar-yen pair extended its downward slide, dipping to 155.29, its lowest level since August 4th, before stabilizing near the 156 handle. This price action...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRMN","MTRA","CLSE","SHRT","WTLS","NTSI","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664587723","title":"AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS","url":"https://stock-news.laohu8.com/highlight/detail?id=2664587723","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664587723?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:25","pubTimestamp":1788441947,"startTime":"0","endTime":"0","summary":"AbbVie (ABBV) announced positive topline results from the Phase 3 Cervino study evaluating etentamig, an investigational BCMA x CD3 bispecific T-ce...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abbvie-announces-phase-3-cervino-study-met-dual-primary-endpoints-of-orr-pfs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abbvie-announces-phase-3-cervino-study-met-dual-primary-endpoints-of-orr-pfs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BLSP4239.USD","LU0124676726.USD","JDOC","LU1585245621.USD","LU0417517546.SGD","LU1057294990.SGD","LU0472753341.HKD","PJP","IE000F7OJYX1.SGD","LU0868494617.USD","LU0057025933.USD","LU2357627491.SGD","LU0820561909.HKD","VHT","LU0942090050.USD","LU1093756325.SGD","BK4585","RXL","LU0912757837.SGD","ORR","AGNG","LU1989772840.SGD","XLV","FTXH","LU0795875169.SGD","ABBV","LU2089284900.SGD","IE0004445239.USD","FHLC","IE00BJJMRZ35.SGD","BK4550","LU0320765646.SGD","BK4559","LU1244550494.USD","MEDX","IYH","LU0256863811.USD","GLAM","LU0965509283.SGD","TRUH","LU0882574055.USD","LU2129689431.USD","LU0203347892.USD","PPH","SG9999011175.SGD","LU1496350171.SGD","IE000WAW04H5.SGD","LU1929549753.HKD","IXJ","LU2237443465.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663600336","title":"Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2663600336","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663600336?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:23","pubTimestamp":1788178980,"startTime":"0","endTime":"0","summary":"CS2009 Achieved Key Clinical Validations for Efficacy and SafetyAs of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient enrollment and longer follow-up, improvements were observed in both the objective response rate  and duration of response :Compelling monotherapy efficacy in first-line non-small cell lung cancer -- At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease. control rate  of 100% in patients with PD-L1 TPS >=50%. In the. broader PD--L1 TPS >=1% population, the ORR was 70.8% and DCR was 91.7%.Monotherapy efficacy in Immunotherapy -pretreated NSCLC and IO-nonresponsive \"cold tumors\" further validates CTLA-4 activity and efficacy.-- In second-line NSCLC patients (all previously treated with IO plus. -- In patients with heavily pretreated metastatic colorectal cancer ,CS2009 monotherap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4567","LU1721428933.USD","LU2211817866.USD","BK1161","LU1223082519.USD","IE00B5TLWC47.USD","ORR","LU2413666699.HKD","LU1093756168.USD","L","BK1574","IE00BFXG0V08.USD","MTD","BK4588","BK4211","LU0053666078.USD","GDXJ","SGDM","LU1223083913.SGD","BK4121","PFS","CDE","IND","LU0210528500.USD","IE00BYQQ9H92.USD","02616","SIL","LU1223082196.USD","LU2487616109.SGD","LU0347712357.USD","BK4017","BK4195","XME","BK4533","LU1093756325.SGD","BK4585","BK4107","LU2413666426.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":33,"pageCount":1,"totalSize":129,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[]}}